<DOC>
	<DOCNO>NCT00563836</DOCNO>
	<brief_summary>Primary evaluation safety , tolerability feasibility regard specific postoperative complication adjuvant treatment catumaxomab administer tumor resection .</brief_summary>
	<brief_title>Phase II Study Trifunctional Antibody Catumaxomab Administered Intra- Postoperatively Patients With Ovarian Cancer</brief_title>
	<detailed_description>An open label , multi-center , single-arm , phase II study accord FlemingÂ´s one-stage design . The surgical procedure Day 0 perform accord AGO State Art , follow one intraoperative four postoperative intraperitoneal administration catumaxomab within 16 day . The Discharge Visit perform patient leave hospital earlier 1 day last infustion , follow End Study Visit Day 30 . Catumaxomab trifunctional antibody target EpCAM tumor cell CD3 T cell . Trifunctional antibody represent new concept target anticancer therapy . This new antibody class capability redirect T cell accessory cell ( e.g . macrophage , dendritic cell [ DCs ] natural killer [ NK ] cell ) tumor site . According preclinical data , trifunctional antibody activate different immune effector cell , trigger complex anti-tumor immune response .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>sign date informed consent form protocolspecific screening procedure patient primary diagnosis epithelial ovarian cancer include clear cell carcinoma ( FIGO IA ( G2G3 ) IV ) Karnofsky index &gt; equal 70 female age 18 year older negative pregnancy test exposure prior cancer therapy specific ovarian cancer previos treatment nonhumanized mouse rat monoclonal antibody know / suspect hypersensitivity catumaxomab similar antibody second malignangcy within last 5 year presence constant immunosuppressive therapy presence symptomatic heart failure occlusive arterial disease inadequate renal hepatic function presence acute chronic systemic infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>catumaxomab</keyword>
	<keyword>phase II</keyword>
	<keyword>intraoperative</keyword>
	<keyword>adjuvant</keyword>
	<keyword>trifunctional antibody</keyword>
</DOC>